- Home
- DMAC
as 12-20-2024 3:34pm EST
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | MINNEAPOLIS |
| Market Cap: | 274.1M | IPO Year: | N/A |
| Target Price: | $7.00 | AVG Volume (30 days): | 118.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.55 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.14 - $6.41 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest DiaMedica Therapeutics Inc. News
DMAC Breaking Stock News: Dive into DMAC Ticker-Specific Updates for Smart Investing
Simply Wall St.
3 days ago
Individual investors are DiaMedica Therapeutics Inc.'s (NASDAQ:DMAC) biggest owners and were hit after market cap dropped US$26m
Business Wire
19 days ago
DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia
Simply Wall St.
a month ago
We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate
Thomson Reuters StreetEvents
a month ago
Q3 2024 DiaMedica Therapeutics Inc Earnings Call
Business Wire
a month ago
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results
Business Wire
a month ago
DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia
Business Wire
a month ago
DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference
Business Wire
2 months ago
DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024
Compare DMAC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DMAC DiaMedica Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.